by myNEO Tx Admin | Apr 30, 2024 | Team events
Over the past few months, we organized our second table football spring cup, bringing together our team for some friendly competition β½οΈIn an intense battle for first place, Bruno Fant emerged victorious against Lore Van Oudenhove. In the small final, Lena Pfitzer...
by myNEO Tx Admin | Mar 8, 2024 | News
Today, on #internationalwomensday , we’re proud to celebrate the remarkable women of myNEO Therapeutics. Their talent, dedication, and leadership are at the heart of our success. Thank you for your invaluable contributions! #womeninhealthcare
by myNEO Tx Admin | Feb 17, 2024 | Team events
Every week we gather for office workouts πββοΈ led by Lien Lybaert. It’s a great way to stay fit and foster a healthy work environment at myNEO Therapeutics. #WorkoutWednesday
by myNEO Tx Admin | Feb 15, 2024 | News
Last week, our team came together for an engaging and informative training session about the cloud-based version of our ImmunoEngine led by Lore Van Oudenhove and Steve Lefever. These training sessions demonstrate our dedication to continuous improvement and knowledge...by myNEO Tx Admin | Nov 29, 2023 | Team
Emiel obtained his bachelor in Biology from the University of Ghent, followed by a Master in Bioinformatics, majoring in Systems Biology. After an elective course piqued his interest in immunology, he decided to pursue his master thesis at the Computational...
The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).